-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA Approves Johnson & Johnson’s AKEEGA for BRCA2-Mutated Metastatic Prostate Cancer

Reuters·12/13/2025 01:26:09

Please log in to view news